The industries conundrum: old models failed, new models are not validated; which one to adopt?
Currently many concepts are in discussion how to implement tranlational sciences, translational research and translational medicine, but none of them are vlidated. In fact, it seems that some of these models are actually emerging from every day experiences of scientific leader's and therefore address the scientific aspect very well, but socioeconomic and managerial challenges off the increasingly complex concepts in the context of decreasing financing are often poorly addressed or completely neglected.
Using the web and collective learning to gather leadership opinion for an ideal world solutions:
InnVentis used the web, and in depth analysis of the scientific and economic literature, interviews with opinion leaders in and in particular the www to generate, what we now consider an optimized model for value creation in high tech industries which rely on repetitive matrix interactions between various scientific centres, units or institutions; i.e. Symbiotic Innovation. The model was repeatedly sent out or posted on the web for discussions, also in comparison with other value creation models and under different names to ensure continued input over more then one year. The whole process took more then three years and started with gathering the experiences from the biotech community and pharmaceutical industries with personal interviews.
The prime goal of InnVentis is increasing the efficacy in preclinical R&D and establishing a new anatomy to create value from science. In order to achieve this, a low-risk research area was selected to test InnVentis' value creation approach in a "field study" to be arranged once appropriate partners are identified. In this context Symbiotic Innovation aims to unravel untapped potential along steroid hormone pathways, nuclear receptors and their modulators. InnVentis' Symbiotic Innovation concepts, however, an idea to be adopted! Symbiotic Innovation creates an unique opportunity to leverage risk and build trusted structures, that secure scientific leadership, while the cost and time are dramatically reduced.
InnVentis' goal is to motivate recognized leaders in the field in order to create virtual competence networks that generates innovative concepts for scientific and medical progress; i.e. value generation in a translational manner supported by the best in their fields.
Motivation and integration of differing and seemingly incompatible interests between academic and commercial organizations will be a key to solve our societies health care problems based on increased exploitation of investments in research deriving from grants or private equity. This will most likely require novel "organic" anatomies that adopt dynamically to a changing environment.
Solving today's pipeline needs will require the reconsideration of established institutions value chains in academia as well as the industry. Cost-effective low risk drug development necessitates the input of leaders in each step of discovery and drug development in an open innovation problem orientated manner. The latter concept, however, contrast with current commercial concepts for the exploitation of knowledge and IP generated within academic, non-profit as well as commercial organization.
InnVentis invites leaders from all disciplines to contribute to a creation of a new translational valuer creating concepts beyond established infrastructures and disciplines.
A vision:
InnVentis proposes that it could be possible to generate and profile a preclinical NCE within 18-24 months, if all leaders in target validation, in silico drug design and validation technologies (off target effects etc.) as well as those in a position to contribute animal models, sample analysis, etc., in general all steps currently considered essential for the safety and efficacy profile of a NCE could be motivated to contribute their know-how to a project focussed along established and previously successfully validated target classes. Furthermore, target validation could be greatly enhanced by an open source exchange of resources and knowledge. Over all, such a model would result in value generation on the basis of societies investments in research. However, InnVentis focus is on validated target, bringing NCEs to a clinical developement stage with minimal costs within short time, while the risk for later stage failure is reduced by attracting scentific leadership.
A cost-covering profit sharing membership model is proposed (see homepage posting for download), that should help all interested participants to become part of a organically organized drug discovery engine without infringing their contractual obligations, but rather securing their justified personal and institutional return on investment.
Non confidential concepts or comments could be be sent to Thomas.Wilckens@InnVentis.com